Literature DB >> 8398712

Prognostic impact of EGF-receptor in papillary thyroid carcinoma.

L A Akslen1, A O Myking, H Salvesen, J E Varhaug.   

Abstract

In this study of papillary thyroid carcinomas, immunopositivity for EGF-receptor was present in a majority of the cases (96%), although different staining patterns were observed. A distinct membraneous reaction was found in 46%, whereas cytoplasmatic positivity of various degrees was present in 90% of the cases. Strong cytoplasmic EGF-receptor staining was significantly associated with extra-thyroidal growth of the primary tumour (P = 0.009), and it was furthermore related to decreased recurrence free survival (P = 0.006). Membraneous EGF-receptor staining was not associated with recurrence free survival or patient survival. Multivariate Cox analysis showed that lymph node metastases (P = 0.0009) and cytoplasmic EGF-receptor staining (P = 0.0048) was independent indicators of tumour recurrences in this group of surgically treated papillary thyroid carcinomas.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8398712      PMCID： PMC1968597          DOI： 10.1038/bjc.1993.432

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  33 in total

1.  Epidermal growth factor, like phorbol esters, induces plasminogen activator in HeLa cells.

Authors:  L S Lee; I B Weinstein
Journal:  Nature       Date:  1978-08-17       Impact factor: 49.962

Review 2.  Epidermal growth factor.

Authors:  G Carpenter; S Cohen
Journal:  Annu Rev Biochem       Date:  1979       Impact factor: 23.643

3.  A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group.

Authors:  D P Byar; S B Green; P Dor; E D Williams; J Colon; H A van Gilse; M Mayer; R J Sylvester; M van Glabbeke
Journal:  Eur J Cancer       Date:  1979-08       Impact factor: 9.162

4.  Prognostic factors of papillary, follicular and medullary carcinomas of the thyroid gland. Retrospective multivariate analysis of 216 patients with a median follow-up of 11 years.

Authors:  J Tennvall; A Biörklund; T Möller; J Ranstam; M Akerman
Journal:  Acta Radiol Oncol       Date:  1985 Jan-Feb

5.  Epidermal growth factor receptors in normal and neoplastic thyroid tissue.

Authors:  Q Y Duh; E T Gum; P L Gerend; S E Raper; O H Clark
Journal:  Surgery       Date:  1985-12       Impact factor: 3.982

6.  Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells.

Authors:  B Westermark; A Magnusson; C H Heldin
Journal:  J Neurosci Res       Date:  1982       Impact factor: 4.164

7.  Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels.

Authors:  S L Fitzpatrick; J Brightwell; J L Wittliff; G H Barrows; G S Schultz
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

8.  Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

Authors:  D E Neal; C Marsh; M K Bennett; P D Abel; R R Hall; J R Sainsbury; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

9.  Long-term results and prognostic factors in patients with differentiated thyroid carcinoma.

Authors:  M Tubiana; M Schlumberger; P Rougier; A Laplanche; E Benhamou; P Gardet; B Caillou; J P Travagli; C Parmentier
Journal:  Cancer       Date:  1985-02-15       Impact factor: 6.860

10.  Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy.

Authors:  M L Carcangiu; G Zampi; A Pupi; A Castagnoli; J Rosai
Journal:  Cancer       Date:  1985-02-15       Impact factor: 6.860
View more
  14 in total

1.  Expression of the estrogen receptor α, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues.

Authors:  Dan Chen; Wenjing Qi; Pengxin Zhang; Hongwei Guan; Lifen Wang
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

2.  Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options.

Authors:  Francesco Perri; Giuseppe Di Lorenzo; Giuseppina Della Vittoria Scarpati; Carlo Buonerba
Journal:  World J Clin Oncol       Date:  2011-03-10

Review 3.  Multi-targeted approach in the treatment of thyroid cancer.

Authors:  B Zarebczan; H Chen
Journal:  Minerva Chir       Date:  2010-02       Impact factor: 1.000

4.  Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells.

Authors:  S Hoffmann; K Maschuw; I Hassan; A Wunderlich; S Lingelbach; A Ramaswamy; L C Hofbauer; A Zielke
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

5.  Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma.

Authors:  Amit Mahipal; Mary J Mcdonald; Agnieszka Witkiewicz; Brian I Carr
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

6.  In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription.

Authors:  Cinzia Puppin; Nadia Passon; Francesco Frasca; Riccardo Vigneri; Federica Tomay; Stefania Tomaciello; Giuseppe Damante
Journal:  Cell Oncol (Dordr)       Date:  2011-01-27       Impact factor: 6.730

Review 7.  The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.

Authors:  Rebecca G Pomerantz; Jennifer Rubin Grandis
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

8.  Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.

Authors:  R Kremser; P Obrist; G Spizzo; H Erler; D Kendler; G Kemmler; G Mikuz; C Ensinger
Journal:  Virchows Arch       Date:  2003-03-08       Impact factor: 4.064

9.  Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer.

Authors:  Aleksander Konturek; Marcin Barczyński; Stanisław Cichoń; Anna Pituch-Noworolska; Jacek Jonkisz; Wojciech Cichoń
Journal:  Langenbecks Arch Surg       Date:  2005-02-03       Impact factor: 3.445

10.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.